Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$24.89M
Enterprise ValueAU$14.22M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Drug Discovery Business ModelOpyl's core focus on AI and data-driven methods targets a durable industry trend: pharmaceutical R&D seeks tools to lower costs and accelerate timelines. A successful platform can scale across sponsors and programs, creating recurring engagement opportunities and long-term demand.
Asset-light Operating FootprintA very small headcount implies an asset-light, low fixed-cost base that can extend runway and make incremental revenue highly operating-levered. If product-market fit improves, the business can scale revenue without proportional increases in payroll expense.
Modest Absolute Debt LevelAlthough shareholders' equity is negative, total debt is described as modest in absolute terms. Lower nominal debt reduces immediate interest and covenant pressure, providing some flexibility for bridge financing or strategic partnerships to support a turnaround.
Bears Say
Severe Revenue ContractionAn ~86% year-over-year revenue decline is a structural red flag: it signals lost customers, failed revenue streams, or collapsing demand. Such erosion makes it difficult to demonstrate sustainable growth, attract partners, or leverage fixed costs toward profitability.
Persistent Negative Cash FlowConsistent negative operating and free cash flow, with material deterioration, indicates the business cannot self-fund operations or growth. This creates ongoing reliance on external financing, raising dilution or refinancing risks and constraining long-term R&D or commercialization plans.
Negative Shareholders' Equity And Fragile Balance SheetNegative equity reflects accumulated losses and weak capitalization, limiting the company's ability to absorb shocks or invest. It increases counterparty and creditor scrutiny, may raise financing costs, and heightens the risk that future funding could be unavailable or dilutive.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$24.89M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 81 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---